Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25953691 | 0.85 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2GAALIMK2 | |
| SCHEMBL25895288 | 0.84 | DPP4 (0.34) | DPP4PREPFAP | |
| SCHEMBL23342596 | 0.84 | MAPT (0.39) | MEN1KMT2ASMN1; SMN2GAALIMK2 | |
| SCHEMBL23324612 | 0.83 | MEN1 (0.37) | MEN1KMT2ASMN1; SMN2GAALIMK2 | |
| SCHEMBL8293473 | 0.80 | DPP4 (0.41) | DPP4PREPFAPKDM4E | |
| SCHEMBL19652262 | 0.78 | SMN1; SMN2 (0.42) | DPP4PREPFAPSMN1; SMN2KDM4E | |
| SCHEMBL22856554 | 0.77 | PIK3CD (0.41) | DPP4PREPFAPSMN1; SMN2KDM4E | |
| SCHEMBL22906377 | 0.76 | EPHX1 (0.39) | DPP4PREPFAPSMN1; SMN2 | |
| SCHEMBL25895287 | 0.76 | DPP4 (0.41) | DPP4PREPFAP | |
| SCHEMBL19652204 | 0.76 | DPP4 (0.41) | DPP4PREPFAPMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | DPP4 3544/4885PREP 2469/4885FAP 304/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | DPP4 3661/4885PREP 3036/4885FAP 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.